HGH (Somatropin)

1. Quick Facts

Property	Value
Category	Growth Hormone / Performance Hormone
Risk Level	Moderate/High
Research Status	Extensive Human Research / Established Hormone Therapy
Administration	Subcutaneous Injection
Typical Frequency	Daily
Estimated Half-Life	Short Plasma Half-Life / Longer IGF-1 Effects
Primary Research Interest	Growth Hormone Deficiency / IGF-1 Signaling / Body Composition / Recovery

Important Disclaimer

This material is provided strictly for educational and informational purposes related to hormone and peptide research. Human Growth Hormone (HGH, Somatropin) is a biologically active hormone capable of significantly altering IGF-1 signaling, metabolism, insulin sensitivity, tissue growth pathways, body composition, and recovery mechanisms. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

2. Summary

Human Growth Hormone (HGH) is a naturally occurring peptide hormone produced by the pituitary gland. It plays a critical role in growth, metabolism, tissue repair, body composition regulation, and insulin-like growth factor-1 (IGF-1) signaling.

Unlike many compounds discussed within peptide communities, HGH possesses one of the largest and most mature evidence bases in endocrinology. Research interest commonly centers around growth hormone deficiency, body composition, metabolism, recovery, bone health, and quality-of-life outcomes.

What People Commonly Claim

Accelerates fat loss
Builds significant muscle mass
Reverses aging
Improves recovery and injury healing
Enhances athletic performance
Improves skin quality
Extends longevity

What the Literature Actually Shows

HGH replacement clearly benefits individuals with documented growth hormone deficiency.
HGH increases IGF-1 signaling and influences body composition.
Changes in lean body mass may partially reflect increased intracellular water.
Performance-enhancement effects are less dramatic than commonly claimed.
Anti-aging claims remain controversial and incompletely supported.
Higher doses increase risks involving glucose regulation, edema, and other adverse effects.
Long-term safety appears favorable when appropriately prescribed and monitored.

CKF Transparency Note: Human Growth Hormone is one of the most extensively studied compounds in the CKF library and has established medical uses for specific growth hormone deficiency states. Evidence strongly supports its role in growth hormone replacement therapy, IGF-1 signaling, body composition, and metabolic regulation. However, many anti-aging, longevity, and performance-enhancement claims extend beyond the strongest available evidence. Readers should distinguish between medically indicated hormone replacement and higher-dose performance-oriented protocols, which may carry substantially different risk profiles and safety considerations.

3. Reconstitution Guide

* Special Measurement Note: This compound is measured in International Units (IU) rather than milligrams (mg). For more information about IU measurements and why some compounds are measured differently, please see the CKF Tide Tables “Weights & Measures” information page.

Vial Size: 36 IU
Dilutant Type: BAC Water
Amount of Dilutant Added: 3 mL
Final Concentration: 12.00 IU/mL

At this concentration:
• 2 IU = 0.167 mL (16.7 units)
• 4 IU = 0.333 mL (33.3 units)
• 8 IU = 0.667 mL (66.7 units)

*Different vial sizes and manufacturers may use different IU strengths. Verify product specifications before calculating concentrations.

4. Route of Administration

Human Growth Hormone is most commonly administered as a subcutaneous injectable hormone.

Primary Route: SubQ Injection
Preferred Timing: Morning fasted or split dosing depending on protocol goals
Administration Notes: Frequently researched in conjunction with training, recovery, body-composition, and endocrine-support protocols.

5. Typical Research Protocols

Product Strength: 12.00 IU/mL
Typical Delivered Amount: 2–4 IU/day for body-composition-oriented research; 4–8 IU/day in higher-intensity performance discussions
Frequency: Daily
Cycle Length: Variable; clinical replacement protocols may be continuous while performance-oriented protocols are often cyclical
Special Notes: HGH typically produces gradual effects over weeks to months rather than days. Early water retention is common and may temporarily obscure body-composition changes. Monitoring glucose regulation and insulin sensitivity becomes increasingly important as dosage increases.

6. Mechanism of Action

HGH functions by activating growth hormone receptors and stimulating downstream production of IGF-1, resulting in widespread effects on metabolism, recovery, tissue repair, and body composition.

IGF-1 signaling enhancement
Tissue repair support
Body composition modulation
Recovery signaling
Bone metabolism support
Metabolic pathway regulation

Many physiological effects attributed to HGH are mediated through downstream IGF-1 signaling rather than HGH itself.

7. Potential Benefits

Potential body composition improvements
Enhanced recovery signaling
Possible connective tissue support
Improved bone-health signaling
Potential fat-mass reduction
Possible quality-of-life improvements in deficient individuals

8. Potential Risks / Side Effects

Moderate/High

Water retention
Edema
Joint discomfort
Carpal tunnel symptoms
Numbness or tingling
Insulin resistance
Blood glucose dysregulation
Potential tissue overgrowth concerns at excessive doses

9. Half-Life

Human Growth Hormone possesses a relatively short circulating plasma half-life.

However, downstream IGF-1 signaling effects persist substantially longer and account for much of HGH’s physiological impact.

10. Storage Information

Store refrigerated before and after reconstitution
Protect from direct light exposure
Avoid excessive agitation during reconstitution
Maintain sterile handling practices during preparation

11. Contraindications / Warnings

Active cancer or malignancy concerns
Uncontrolled diabetes
Severe diabetic retinopathy
Acute critical illness
Pregnancy or breastfeeding
Known hypersensitivity to HGH products

12. Further Study

Current Evidence Gaps

Long-term anti-aging outcomes
Longevity effects in healthy individuals
Performance enhancement in non-deficient populations
Optimal dosing strategies outside medical replacement therapy
Long-term outcomes of supraphysiologic dosing

13. Research References

PubMed
PubMed Central (PMC)
NIH Publications
Endocrinology literature
Sports medicine literature
Growth hormone and IGF-1 research literature

14. Last Reviewed

June 2026